Published by Global Banking & Finance Review®
Posted on July 24, 2025
1 min readLast updated: January 22, 2026
Add as preferred source on GoogleBavarian Nordic is in takeover talks with Nordic Capital and Permira, causing a 24% share price increase. The biotech firm is key in global vaccine supply.
COPENHAGEN (Reuters) -Danish biotech Bavarian Nordic said on Thursday it is in discussions with a consortium of Nordic Capital and Permira regarding a potential takeover offer from the two private equity groups, sending its share price up 24%.
"As these discussions are continuing, there can be no certainty as to whether any offer for Bavarian Nordic A/S by Nordic Capital and Permira will be made, or the timing or the terms of such offer," the vaccine maker said in a statement.
Bavarian Nordic, which specialises in vaccines for mpox, smallpox and other infectious diseases, has a market capitalisation of close to $3.0 billion following Thursday's share price rally, a Reuters calculation showed.
The company did not disclose how much the private equity groups might offer for its shares.
Bavarian is a key supplier to governments globally, including the United States, where it contributes to public health preparedness programmes.
(Reporting by Stine Jacobsen, editing by Terje Solsvik, Kirsten Donovan)
Bavarian Nordic is in discussions with a consortium of Nordic Capital and Permira regarding a potential takeover offer.
Following Thursday's share price rally, Bavarian Nordic has a market capitalisation of close to $3.0 billion.
Bavarian Nordic specializes in vaccines for mpox, smallpox, and other infectious diseases.
Bavarian Nordic is a key supplier to governments globally, including the United States, contributing to public health preparedness programmes.
As the discussions are ongoing, there can be no certainty regarding whether any offer for Bavarian Nordic A/S will be made, or the timing or terms of such an offer.
Explore more articles in the Finance category
